Economic endpoints in clinical trials.
Economic endpoints are increasingly common in randomized clinical trials. As a relatively new addition to the field, methods of measuring and analyzing cost data are still evolving. These developments will be stimulated by the demands of the public for efficient and effective medical care, which will be based on the findings of clinical trials.
Hlatky
Mark A
MA
Department of Health Research and Policy, Department of Medicine, Stanford University School of Medicine, HRP Redwood Building, Room 150, Stanford, CA 94305-5405, USA. hlatky@stanford.edu
D003362:Cost-Benefit Analysis / Q000706:statistics & numerical data*; D003365:Costs and Cost Analysis; D003627:Data Interpretation, Statistical; D006295:Health Resources / Q000191:economics; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D014481:United States